HDAC2 and teratoma: Importantly, immunoexpression of these HDACs was particularly high in cisplatin-exposed metastatic samples, with 10/14 (71.4%) and 13/14 (92.9%) tumors with strong immunoexpression of HDAC1 and HDAC2, respectively (Figure 2E, including 4/6 and 6/6 of non-teratoma cases, specifically).